{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:05:53Z","timestamp":1794578753110,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["Z220022"],"award-info":[{"award-number":["Z220022"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009331","name":"Beijing Hospitals Authority Clinical Medicine Development of special funding support","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41591-025-03792-7","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:03:52Z","timestamp":1752138232000},"page":"3485-3491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["A bispecific antibody\u2013drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9388-4180","authenticated-orcid":false,"given":"Chang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4914-6508","authenticated-orcid":false,"given":"Meili","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shegan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diansheng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4030-8600","authenticated-orcid":false,"given":"Yanshuo","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-3768","authenticated-orcid":false,"given":"Changsong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9614-6279","authenticated-orcid":false,"given":"Jiajia","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9333-3255","authenticated-orcid":false,"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6936-2622","authenticated-orcid":false,"given":"Xiaotian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3798-7024","authenticated-orcid":false,"given":"Jifang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-2922","authenticated-orcid":false,"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5588-5657","authenticated-orcid":false,"given":"Zhihao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"3792_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"3792_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan, E. et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology 163, 649\u2013658.e642 (2022).","journal-title":"Gastroenterology"},{"key":"3792_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki, Y. et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med. 386, 449\u2013462 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3792_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun, J. M. et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398, 759\u2013771 (2021).","journal-title":"Lancet"},{"key":"3792_CR5","doi-asserted-by":"publisher","first-page":"e068714","DOI":"10.1136\/bmj-2021-068714","volume":"377","author":"Z Lu","year":"2022","unstructured":"Lu, Z. et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. Br. Med. J. 377, e068714 (2022).","journal-title":"Br. Med. J."},{"key":"3792_CR6","doi-asserted-by":"publisher","first-page":"e7235","DOI":"10.1002\/cam4.7235","volume":"13","author":"K Kato","year":"2024","unstructured":"Kato, K. et al. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. Cancer Med 13, e7235 (2024).","journal-title":"Cancer Med"},{"key":"3792_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","volume":"21","author":"TK Kim","year":"2022","unstructured":"Kim, T. K., Vandsemb, E. N., Herbst, R. S. & Chen, L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat. Rev. Drug Discov. 21, 529\u2013540 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3792_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.4637","volume":"5","author":"N Zhuo","year":"2022","unstructured":"Zhuo, N. et al. Characteristics and prognosis of acquired resistance to immune checkpoint inhibitors in gastrointestinal cancer. JAMA Netw. Open 5, e224637 (2022).","journal-title":"JAMA Netw. Open"},{"key":"3792_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. & Hellmann, M. D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37, 443\u2013455 (2020).","journal-title":"Cancer Cell"},{"key":"3792_CR10","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang, J. et al. Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 21, 832\u2013842 (2020).","journal-title":"Lancet Oncol."},{"key":"3792_CR11","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.21.01926","volume":"40","author":"L Shen","year":"2022","unstructured":"Shen, L. et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J. Clin. Oncol. 40, 3065\u20133076 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3792_CR12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","volume":"25","author":"CL Arteaga","year":"2014","unstructured":"Arteaga, C. L. & Engelman, J. A. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25, 282\u2013303 (2014).","journal-title":"Cancer Cell"},{"key":"3792_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0790-4","volume":"17","author":"MK Kashyap","year":"2018","unstructured":"Kashyap, M. K. & Abdel-Rahman, O. Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma. Mol. Cancer 17, 54 (2018).","journal-title":"Mol. Cancer"},{"key":"3792_CR14","doi-asserted-by":"publisher","first-page":"6257","DOI":"10.2147\/OTT.S111691","volume":"9","author":"J Song","year":"2016","unstructured":"Song, J. et al. Epidermal growth factor receptor and B7-H3 expression in esophageal squamous tissues correlate to patient prognosis. OncoTargets Ther. 9, 6257\u20136263 (2016).","journal-title":"OncoTargets Ther."},{"key":"3792_CR15","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/ijc.21454","volume":"118","author":"M Hanawa","year":"2006","unstructured":"Hanawa, M. et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int. J. Cancer 118, 1173\u20131180 (2006).","journal-title":"Int. J. Cancer"},{"key":"3792_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/sj.bjc.6602625","volume":"93","author":"L Gibault","year":"2005","unstructured":"Gibault, L. et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br. J. Cancer 93, 107\u2013115 (2005).","journal-title":"Br. J. Cancer"},{"key":"3792_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.annonc.2019.10.018","volume":"31","author":"M Moehler","year":"2020","unstructured":"Moehler, M. et al. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO\/EORTC trial (POWER). Ann. Oncol. 31, 228\u2013235 (2020).","journal-title":"Ann. Oncol."},{"key":"3792_CR18","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S1470-2045(14)70024-5","volume":"15","author":"SJ Dutton","year":"2014","unstructured":"Dutton, S. J. et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 15, 894\u2013904 (2014).","journal-title":"Lancet Oncol."},{"key":"3792_CR19","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/annonc\/mdp069","volume":"20","author":"S Lorenzen","year":"2009","unstructured":"Lorenzen, S. et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann. Oncol. 20, 1667\u20131673 (2009).","journal-title":"Ann. Oncol."},{"key":"3792_CR20","first-page":"100239","volume":"3","author":"Z Lu","year":"2022","unstructured":"Lu, Z. et al. Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial. Innovation (Camb.) 3, 100239 (2022).","journal-title":"Innovation (Camb.)"},{"key":"3792_CR21","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.biopha.2014.08.011","volume":"68","author":"L Wang","year":"2014","unstructured":"Wang, L., Yuan, H., Li, Y. & Han, Y. The role of HER3 in gastric cancer. Biomed. Pharmacother. 68, 809\u2013812 (2014).","journal-title":"Biomed. Pharmacother."},{"key":"3792_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-46","volume":"6","author":"P Kountourakis","year":"2006","unstructured":"Kountourakis, P. et al. Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 6, 46 (2006).","journal-title":"BMC Cancer"},{"key":"3792_CR23","doi-asserted-by":"publisher","first-page":"6309","DOI":"10.1158\/1538-7445.AM2023-6309","volume":"83","author":"B Renshaw","year":"2023","unstructured":"Renshaw, B., Khalili, J. S., Xiao, S. & Zhu, Y. Abstract 6309: Anti-tumor efficacy of SI-B001, a novel EGFR \u00d7 HER3 bispecific antibody, against EGFR-driven epithelial tumors alone or in combination with paclitaxel and carboplatin. Cancer Res. 83, 6309 (2023).","journal-title":"Cancer Res."},{"key":"3792_CR24","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1042\/BST20140043","volume":"42","author":"J Claus","year":"2014","unstructured":"Claus, J., Patel, G., Ng, T. & Parker, P. J. A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy. Biochem. Soc. Trans. 42, 831\u2013836 (2014).","journal-title":"Biochem. Soc. Trans."},{"key":"3792_CR25","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1158\/1078-0432.CCR-17-0646","volume":"24","author":"AG Hill","year":"2018","unstructured":"Hill, A. G. et al. Phase II study of the dual EGFR\/HER3 inhibitor duligotuzumab (MEHD7945A) versus cetuximab in combination with FOLFIRI in second-line RAS wild-type metastatic colorectal cancer. Clin. Cancer Res. 24, 2276\u20132284 (2018).","journal-title":"Clin. Cancer Res."},{"key":"3792_CR26","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1001\/jamaoncol.2022.0503","volume":"8","author":"MZ Qiu","year":"2022","unstructured":"Qiu, M. Z. et al. Evaluation of safety of treatment with anti\u2013epidermal growth factor receptor antibody drug conjugate MRG003 in patients with advanced solid tumors: a phase 1 nonrandomized clinical trial. JAMA Oncol. 8, 1042\u20131046 (2022).","journal-title":"JAMA Oncol."},{"key":"3792_CR27","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1200\/JCO.23.01476","volume":"41","author":"HA Yu","year":"2023","unstructured":"Yu, H. A. et al. HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor\u2013mutated non\u2013small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J. Clin. Oncol. 41, 5363\u20135375 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3792_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","volume":"12","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne, P. A. et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov. 12, 74\u201389 (2022).","journal-title":"Cancer Discov."},{"key":"3792_CR29","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1016\/j.xphs.2020.06.015","volume":"109","author":"J Xue","year":"2020","unstructured":"Xue, J. et al. Prediction of human pharmacokinetics and clinical effective dose of SI-B001, an EGFR\/HER3 bi-specific monoclonal antibody. J. Pharm. Sci. 109, 3172\u20133180 (2020).","journal-title":"J. Pharm. Sci."},{"key":"3792_CR30","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1158\/1538-7445.AM2023-2642","volume":"83","author":"W Wan","year":"2023","unstructured":"Wan, W. et al. Abstract 2642: BL-B01D1, a novel EGFR\u00d7HER3-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation. Cancer Res. 83, 2642 (2023).","journal-title":"Cancer Res."},{"key":"3792_CR31","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","volume":"25","author":"Y Ma","year":"2024","unstructured":"Ma, Y. et al. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 25, 901\u2013911 (2024).","journal-title":"Lancet Oncol."},{"key":"3792_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nrclinonc.2015.200","volume":"13","author":"P Anandavadivelan","year":"2016","unstructured":"Anandavadivelan, P. & Lagergren, P. Cachexia in patients with oesophageal cancer. Nat. Rev. Clin. Oncol. 13, 185\u2013198 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3792_CR33","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/01635581.2012.670743","volume":"64","author":"A Attar","year":"2012","unstructured":"Attar, A. et al. Malnutrition is high and underestimated during chemotherapy in gastrointestinal cancer: an AGEO prospective cross-sectional multicenter study. Nutr. Cancer 64, 535\u2013542 (2012).","journal-title":"Nutr. Cancer"},{"key":"3792_CR34","doi-asserted-by":"publisher","first-page":"114328","DOI":"10.1016\/j.ejca.2024.114328","volume":"212","author":"X Meng","year":"2024","unstructured":"Meng, X. et al. Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): a single-arm, phase II study. Eur. J. Cancer 212, 114328 (2024).","journal-title":"Eur. J. Cancer"},{"key":"3792_CR35","doi-asserted-by":"publisher","first-page":"109679","DOI":"10.1016\/j.radonc.2023.109679","volume":"184","author":"W Zhao","year":"2023","unstructured":"Zhao, W. et al. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: an open-label, single-arm, phase II trial. Radiother. Oncol. 184, 109679 (2023).","journal-title":"Radiother. Oncol."},{"key":"3792_CR36","doi-asserted-by":"publisher","first-page":"567486","DOI":"10.1155\/2009\/567486","volume":"2009","author":"A Harandi","year":"2009","unstructured":"Harandi, A., Zaidi, A. S., Stocker, A. M. & Laber, D. A. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J. Oncol. 2009, 567486 (2009).","journal-title":"J. Oncol."},{"key":"3792_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/849051","volume":"2009","author":"M Giovannini","year":"2009","unstructured":"Giovannini, M. et al. Clinical significance of skin toxicity due to EGFR-targeted therapies. J. Oncol. 2009, 849051 (2009).","journal-title":"J. Oncol."},{"key":"3792_CR38","unstructured":"Expansion Cohorts: Use in First-in-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics Guidance for Industry (United States Food and Drug Administration, 2022); www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/expansion-cohorts-use-first-human-clinical-trials-expedite-development-oncology-drugs-and-biologics"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03792-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03792-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03792-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T14:02:41Z","timestamp":1760623361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03792-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3792"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03792-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.Z., H.Z. and S.X. are employees of Sichuan Baili Pharmaceutical. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}